Tags

Type your tag names separated by a space and hit enter

Therapeutic potential of cannabinoids in the treatment of neuroinflammation associated with Parkinson's disease.
Mini Rev Med Chem 2011; 11(7):582-90MR

Abstract

The cannabinoid system is represented by two principal receptor subtypes, termed CB1 and CB2, along with several endogenous ligands. In the central nervous system it is involved in several processes. CB1 receptors are mainly expressed by neurons and their activation is primarily implicated in psychotropic and motor effects of cannabinoids. CB2 receptors are expressed by glial cells and are thought to participate in regulation of neuroimmune reactions. This review aims to highlight several reported properties of cannabinoids that could be used to inhibit the adverse neuroinflammatory processes contributing to Parkinson's disease and possibly other neurodegenerative disorders. These include anti-oxidant properties of phytocannabinoids and synthetic cannabinoids as well as hypothermic and antipyretic effects. However, cannabinoids may also trigger signaling cascades leading to impaired mitochondrial enzyme activity, reduced mitochondrial biogenesis, and increased oxidative stress, all of which could contribute to neurotoxicity. Therefore, further pharmacological studies are needed to allow rational design of new cannabinoid-based drugs lacking detrimental in vivo effects.

Authors+Show Affiliations

Department of Biology, University of British Columbia Okanagan, Kelowna, BC, Canada.No affiliation info availableNo affiliation info available

Pub Type(s)

Journal Article
Research Support, Non-U.S. Gov't
Review

Language

eng

PubMed ID

21699489

Citation

Little, J P., et al. "Therapeutic Potential of Cannabinoids in the Treatment of Neuroinflammation Associated With Parkinson's Disease." Mini Reviews in Medicinal Chemistry, vol. 11, no. 7, 2011, pp. 582-90.
Little JP, Villanueva EB, Klegeris A. Therapeutic potential of cannabinoids in the treatment of neuroinflammation associated with Parkinson's disease. Mini Rev Med Chem. 2011;11(7):582-90.
Little, J. P., Villanueva, E. B., & Klegeris, A. (2011). Therapeutic potential of cannabinoids in the treatment of neuroinflammation associated with Parkinson's disease. Mini Reviews in Medicinal Chemistry, 11(7), pp. 582-90.
Little JP, Villanueva EB, Klegeris A. Therapeutic Potential of Cannabinoids in the Treatment of Neuroinflammation Associated With Parkinson's Disease. Mini Rev Med Chem. 2011;11(7):582-90. PubMed PMID: 21699489.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Therapeutic potential of cannabinoids in the treatment of neuroinflammation associated with Parkinson's disease. AU - Little,J P, AU - Villanueva,E B, AU - Klegeris,A, PY - 2011/03/14/received PY - 2011/03/31/accepted PY - 2011/6/25/entrez PY - 2011/6/28/pubmed PY - 2011/10/7/medline SP - 582 EP - 90 JF - Mini reviews in medicinal chemistry JO - Mini Rev Med Chem VL - 11 IS - 7 N2 - The cannabinoid system is represented by two principal receptor subtypes, termed CB1 and CB2, along with several endogenous ligands. In the central nervous system it is involved in several processes. CB1 receptors are mainly expressed by neurons and their activation is primarily implicated in psychotropic and motor effects of cannabinoids. CB2 receptors are expressed by glial cells and are thought to participate in regulation of neuroimmune reactions. This review aims to highlight several reported properties of cannabinoids that could be used to inhibit the adverse neuroinflammatory processes contributing to Parkinson's disease and possibly other neurodegenerative disorders. These include anti-oxidant properties of phytocannabinoids and synthetic cannabinoids as well as hypothermic and antipyretic effects. However, cannabinoids may also trigger signaling cascades leading to impaired mitochondrial enzyme activity, reduced mitochondrial biogenesis, and increased oxidative stress, all of which could contribute to neurotoxicity. Therefore, further pharmacological studies are needed to allow rational design of new cannabinoid-based drugs lacking detrimental in vivo effects. SN - 1875-5607 UR - https://www.unboundmedicine.com/medline/citation/21699489/Therapeutic_potential_of_cannabinoids_in_the_treatment_of_neuroinflammation_associated_with_Parkinson's_disease_ L2 - http://www.eurekaselect.com/88182/article DB - PRIME DP - Unbound Medicine ER -